Mehdi Touat

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026

Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.

Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.

Journal: Science translational medicine
Published: August 05, 2026

Exploring the landscape of targetable alterations in patients with glioblastoma.

Exploring the landscape of targetable alterations in patients with glioblastoma.

Journal: Nature reviews. Clinical oncology
Published: July 20, 2026

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 22, 2026

Brainstem tumours and invasive mechanical ventilation: Lessons from a single-centre cohort.

Brainstem tumours and invasive mechanical ventilation: Lessons from a single-centre cohort.

Journal: Clinical neurology and neurosurgery
Published: April 01, 2026

Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 cases.

Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 cases.

Journal: Neuro-oncology practice
Published: March 09, 2026

cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.

cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.

Journal: Neuro-oncology
Published: February 25, 2026

Clinical responses to trastuzumab deruxtecan in molecularly defined ependymoma.

Clinical responses to trastuzumab deruxtecan in molecularly defined ependymoma.

Journal: NPJ precision oncology
Published: January 23, 2026

RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma.

RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma.

Journal: bioRxiv : the preprint server for biology
Published: January 16, 2026

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Journal: Journal of neuro-oncology
Published: November 25, 2025

Dramatic response to entrectinib in a rare glioneuronal tumor harboring an NTRK2 fusion.

Dramatic response to entrectinib in a rare glioneuronal tumor harboring an NTRK2 fusion.

Journal: The oncologist
Published: October 09, 2025

Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.

Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.

Journal: Nature communications
Published: October 09, 2025
Showing 1-12 of 130

Last Updated: 09/26/2026